Share on LinkedInShare on LinkedIn

ARTICLE · 21 MARCH 2025

Let´s Talk About „about" And Numerical Data

Maucher Jenkins
Maucher Jenkins
Contributor
Maucher Jenkins

Maucher Jenkins

The team at Maucher Jenkins helps businesses gain a competitive edge by safeguarding and enhancing...

View firm profile
Explore more from Maucher Jenkins

This relates to a Federal Court Decision in Canada Boehringer Ingelheim (Canada) Ltd. v. Jamp Pharma Corporation, issued on Aug. 8, 2024, Citation 2024 FC 1198, which is a recent decision involving interpretation.

CanadaIntellectual Property

This relates to a Federal Court Decision in Canada Boehringer Ingelheim (Canada) Ltd. v. Jamp Pharma Corporation, issued on Aug. 8, 2024, Citation 2024 FC 1198, which is a recent decision involving interpretation of numerical data in claims (including single numbers and number ranges).

See  document.do

We discuss here only one of the patents encompassed in the decision and the issue of interpretation of numeric data in claims which was part of the decision: CA 2,726,267 [267 Patent]  Espacenet - Originaldokument

The 267 Patent describes the invention of the patent as relating to a suspension formulation containing the active substance Nintedanib esylate, a capsule containing the formulation, a process for preparing the formulation and capsule, and packaging material for the capsule (267 Patent, Ex2, 1:4-9). More particularly, the invention is described as relating to formulations of Nintedanib esylate (Nintendanib hereinafter) containing lipid suspensions

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from